rofecoxib has been researched along with Lung Neoplasms in 9 studies
Lung Neoplasms: Tumors or cancer of the LUNG.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Gefitinib 250 mg/d was combined with rofecoxib (dose escalated from 12." | 2.73 | Combination therapy with gefitinib and rofecoxib in patients with platinum-pretreated relapsed non small-cell lung cancer. ( Botwood, N; Carbone, D; Danson, S; Dunlop, D; O'Byrne, KJ; Ranson, M; Taguchi, F, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (88.89) | 29.6817 |
| 2010's | 1 (11.11) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Patel, S | 1 |
| Vetale, S | 1 |
| Teli, P | 1 |
| Mistry, R | 1 |
| Chiplunkar, S | 1 |
| Peluffo, GD | 1 |
| Stillitani, I | 1 |
| Rodríguez, VA | 1 |
| Diament, MJ | 1 |
| Klein, SM | 1 |
| Tanaka, T | 1 |
| Delong, PA | 1 |
| Amin, K | 1 |
| Henry, A | 1 |
| Kruklitis, R | 1 |
| Kapoor, V | 1 |
| Kaiser, LR | 1 |
| Albelda, SM | 1 |
| Spano, JP | 1 |
| Chouahnia, K | 1 |
| Morère, JF | 1 |
| Kozak, KR | 1 |
| Milne, GL | 1 |
| Morrow, JD | 1 |
| Cuiffo, BP | 1 |
| Gridelli, C | 1 |
| Gallo, C | 1 |
| Ceribelli, A | 1 |
| Gebbia, V | 1 |
| Gamucci, T | 1 |
| Ciardiello, F | 1 |
| Carozza, F | 1 |
| Favaretto, A | 1 |
| Daniele, B | 1 |
| Galetta, D | 1 |
| Barbera, S | 1 |
| Rosetti, F | 1 |
| Rossi, A | 1 |
| Maione, P | 1 |
| Cognetti, F | 1 |
| Testa, A | 1 |
| Di Maio, M | 1 |
| Morabito, A | 1 |
| Perrone, F | 1 |
| Harris, RE | 1 |
| Beebe-Donk, J | 1 |
| Alshafie, GA | 1 |
| Alam, M | 1 |
| Wang, JH | 1 |
| Coffey, JC | 1 |
| Qadri, SS | 1 |
| O'Donnell, A | 1 |
| Aherne, T | 1 |
| Redmond, HP | 1 |
| O'Byrne, KJ | 1 |
| Danson, S | 1 |
| Dunlop, D | 1 |
| Botwood, N | 1 |
| Taguchi, F | 1 |
| Carbone, D | 1 |
| Ranson, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase II-III, Factorial Multicenter Randomized Trial Evaluating the Addition of Rofecoxib to Polycht With Cispatin and Gemcitabine and Fixed Dose Rate Infusion of Gem in Association With Cisplatin in 1st-line for Advanced NSCLC[NCT00385606] | Phase 2/Phase 3 | 400 participants (Actual) | Interventional | 2003-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for rofecoxib and Lung Neoplasms
| Article | Year |
|---|---|
[Cyclooxygenase 2 inhibitors and lung carcinoma].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cele | 2004 |
2 trials available for rofecoxib and Lung Neoplasms
| Article | Year |
|---|---|
Factorial phase III randomised trial of rofecoxib and prolonged constant infusion of gemcitabine in advanced non-small-cell lung cancer: the GEmcitabine-COxib in NSCLC (GECO) study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; | 2007 |
Combination therapy with gefitinib and rofecoxib in patients with platinum-pretreated relapsed non small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small | 2007 |
6 other studies available for rofecoxib and Lung Neoplasms
| Article | Year |
|---|---|
IL-10 production in non-small cell lung carcinoma patients is regulated by ERK, P38 and COX-2.
Topics: Antibodies, Monoclonal; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Cyclooxygenase 2; Cycloo | 2012 |
Reduction of tumor progression and paraneoplastic syndrome development in murine lung adenocarcinoma by nonsteroidal antiinflammatory drugs.
Topics: Adenocarcinoma; Animals; Anti-Inflammatory Agents, Non-Steroidal; Cell Division; Cell Survival; Chem | 2004 |
Treatment of lung cancer using clinically relevant oral doses of the cyclooxygenase-2 inhibitor rofecoxib: potential value as adjuvant therapy after surgery.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tum | 2005 |
Hypertrophic osteoarthropathy pathogenesis: a case highlighting the potential role for cyclo-oxygenase-2-derived prostaglandin E2.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dinoprostone; F | 2006 |
Reduced risk of human lung cancer by selective cyclooxygenase 2 (COX-2) blockade: results of a case control study.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Case-Control Studies; Celecoxib; Chem | 2007 |
Characterization of the effects of cyclooxygenase-2 inhibition in the regulation of apoptosis in human small and non-small cell lung cancer cell lines.
Topics: Analysis of Variance; Apoptosis; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small | 2007 |